{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:23:35Z","timestamp":1793298215177,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.annonc.2021.01.003","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T09:01:03Z","timestamp":1611046863000},"page":"439-451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":257,"title":["Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606"],"prefix":"10.1016","volume":"32","author":[{"given":"E.","family":"Baudin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Caplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Garcia-Carbonero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ferolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"Filosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Frilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.W.","family":"de Herder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"H\u00f6rsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Knigge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Korse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lombard-Bohas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.Y.","family":"Scoazec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2021.01.003_bib1","series-title":"Classification of Tumours of the Lung, Pleura, Thymus and Heart","year":"2015"},{"key":"10.1016\/j.annonc.2021.01.003_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib3","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.ejca.2012.12.022","article-title":"Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry","volume":"49","author":"Korse","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.01.003_bib4","doi-asserted-by":"crossref","first-page":"S1435","DOI":"10.21037\/jtd.2017.09.83","article-title":"Surgical treatment of low and intermediate grade lung net","volume":"9","author":"Garc\u00eda-Yuste","year":"2017","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.annonc.2021.01.003_bib5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejcts.2006.11.031","article-title":"Typical and atypical carcinoid tumours: analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung","volume":"31","author":"Garc\u00eda-Yuste","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/ejcts\/ezu495","article-title":"Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group","volume":"48","author":"Filosso","year":"2015","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/ejcts\/ezu404","article-title":"Clinical management of atypical carcinoid and large-cell neuroendocrine carcinoma: a multicentre study on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours of the Lung Working Group","volume":"48","author":"Filosso","year":"2015","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0000000000000419","article-title":"Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis","volume":"10","author":"Steuer","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib9","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.athoracsur.2014.08.030","article-title":"Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors","volume":"99","author":"Nussbaum","year":"2015","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib10","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.athoracsur.2017.05.011","article-title":"Adjuvant chemotherapy does not confer superior survival in patients with atypical carcinoid tumors","volume":"104","author":"Anderson","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib11","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/SLA.0b013e3181dd4ec4","article-title":"Thymic neuroendocrine tumors: a SEER database analysis of 160 patients","volume":"251","author":"Gaur","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtcvs.2014.08.061","article-title":"Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases","volume":"149","author":"Filosso","year":"2015","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib13","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.athoracsur.2016.07.050","article-title":"Neuroendocrine tumors of the thymus: analysis of factors affecting survival in 254 patients","volume":"103","author":"Sullivan","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib14","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1210\/jc.2014-1560","article-title":"Natural course and survival of neuroendocrine tumors of thymus and lung in MEN1 patients","volume":"99","author":"de Laat","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.annonc.2021.01.003_bib15","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/cen.13480","article-title":"Clinical features and prognosis of thymic neuroendocrine tumours associated with multiple endocrine neoplasia type 1: a single-centre study, systematic review and meta-analysis","volume":"87","author":"Ye","year":"2017","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.annonc.2021.01.003_bib16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000435921","article-title":"Bronchopulmonary neuroendocrine neoplasms and their precursor lesions in multiple endocrine neoplasia type 1","volume":"103","author":"Bartsch","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.annonc.2021.01.003_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00268-017-4135-z","article-title":"Histologically proven bronchial neuroendocrine tumors in MEN1: a GTE 51-case cohort study","volume":"42","author":"Lecomte","year":"2018","journal-title":"World J Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/ejcts\/ezt470","article-title":"Prognostic factors in a multicentre study of 247 atypical pulmonary carcinoids","volume":"45","author":"Daddi","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib19","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib20","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S1470-2045(17)30681-2","article-title":"Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial","volume":"18","author":"Ferolla","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib21","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jtcvs.2005.05.041","article-title":"The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors","volume":"130","author":"Lim","year":"2005","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib22","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/ejcts\/ezaa018","article-title":"Molecular identification of bronchopulmonary neuroendocrine tumours and neuroendocrine genotype in lung neoplasia using the NETest liquid biopsy","volume":"57","author":"Filosso","year":"2020","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/JTO.0b013e318197f2e7","article-title":"Tumorlets, multicentric carcinoids, lymph-nodal metastases, and long-term behavior in bronchial carcinoids","volume":"4","author":"Ferolla","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib24","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1097\/PAS.0000000000001033","article-title":"Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) syndrome and carcinoid tumors with\/without NECH: a clinicopathologic, radiologic, and immunomolecular comparison study","volume":"42","author":"Mengoli","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annonc.2021.01.003_bib25","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA","volume":"44","author":"Bozkurt","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.annonc.2021.01.003_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13550-015-0130-2","article-title":"Somatostatin receptor PET\/CT in restaging of typical and atypical lung carcinoids","volume":"5","author":"Prasad","year":"2015","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.annonc.2021.01.003_bib27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000472717","article-title":"68Gallium DOTANOC-PET imaging in lung carcinoids: impact on patients' management","volume":"106","author":"Lamarca","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.annonc.2021.01.003_bib28","first-page":"446","article-title":"Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumors","volume":"59","author":"Gasparri","year":"2015","journal-title":"Q\u00a0J Nucl Med Mol Imaging"},{"key":"10.1016\/j.annonc.2021.01.003_bib29","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/ejcts\/ezw422","article-title":"Is there a role for traditional nuclear medicine imaging in the management of pulmonary carcinoid tumours?","volume":"51","author":"Cattoni","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib30","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/thoraxjnl-2014-205899","article-title":"Test performance of PET-CT for mediastinal lymph node staging of pulmonary carcinoid tumours","volume":"70","author":"Pattenden","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.annonc.2021.01.003_bib31","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41571-019-0253-x","article-title":"Global Consultation on Cancer Staging: promoting consistent understanding and use","volume":"6","author":"Brierley","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ejcts\/ezx037","article-title":"Comparison of clinical features and survival between thymic carcinoma and thymic carcinoid patients","volume":"52","author":"Zhao","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1309\/3PDN-PMT5-EQTM-H0CD","article-title":"Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases","volume":"114","author":"Moran","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.annonc.2021.01.003_bib34","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2021.01.003_bib35","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib36","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/gcc.22183","article-title":"Tumor genetics and survival of thymic neuroendocrine neoplasms: a multi-institutional clinicopathologic study","volume":"53","author":"Str\u00f6bel","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.annonc.2021.01.003_bib37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.lungcan.2012.12.001","article-title":"Treatment, prognostic markers and survival in thymic neuroendocrine tumours. A study from a single tertiary referral centre","volume":"79","author":"Crona","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2021.01.003_bib38","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1038\/ncomms4518","article-title":"Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids","volume":"5","author":"Fernandez-Cuesta","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2021.01.003_bib39","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/path.4853","article-title":"Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D","volume":"241","author":"Simbolo","year":"2017","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.annonc.2021.01.003_bib40","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.jtho.2019.05.003","article-title":"Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations","volume":"14","author":"Simbolo","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1159\/000502776","article-title":"Classification and prognostic stratification of bronchopulmonary neuroendocrine neoplasms","volume":"110","author":"Oka","year":"2020","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.annonc.2021.01.003_bib42","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1530\/ERC-13-0027","article-title":"Are G3 ENETS neuroendocrine neoplasms heterogeneous?","volume":"20","author":"V\u00e9layoudom-C\u00e9phise","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.annonc.2021.01.003_bib43","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/s41379-019-0248-2","article-title":"Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices","volume":"32","author":"Rekhtman","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annonc.2021.01.003_bib44","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jtho.2019.04.015","article-title":"Molecular classification of neuroendocrine tumors of the thymus","volume":"14","author":"Dinter","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.lungcan.2019.03.013","article-title":"Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence","volume":"132","author":"Gr\u00f8ndahl","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2021.01.003_bib46","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jtho.2018.10.166","article-title":"Evaluation of the prognostic significance of TNM staging guidelines in lung carcinoid tumors","volume":"14","author":"Yoon","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib47","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jtho.2019.02.002","article-title":"Characterization, prognosis, and treatment of patients with metastatic lung carcinoid tumors","volume":"14","author":"Robelin","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib48","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.athoracsur.2018.05.044","article-title":"Incidence and prognostic significance of carcinoid lymph node metastases","volume":"106","author":"Kneuertz","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib49","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/00000478-199808000-00003","article-title":"Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid","volume":"22","author":"Travis","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annonc.2021.01.003_bib50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jtcvs.2017.08.102","article-title":"Improvement in TNM staging of pulmonary neuroendocrine tumors requires histology and regrouping of tumor size","volume":"155","author":"Cattoni","year":"2018","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib51","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000480015","article-title":"Natural history of localized and locally advanced atypical lung carcinoids after complete resection: a joined French-Italian retrospective multicenter study","volume":"106","author":"Marciello","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.annonc.2021.01.003_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-13-0246","article-title":"Grading the neuroendocrine tumors of the lung: an evidence-based proposal","volume":"21","author":"Rindi","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.annonc.2021.01.003_bib53","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00428-017-2177-0","article-title":"Distinctive pathological and clinical features of lung carcinoids with high proliferation index","volume":"471","author":"Marchi\u00f2","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.annonc.2021.01.003_bib54","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1378\/chest.14-1960","article-title":"Natural history of typical pulmonary carcinoid tumors: a comparison of nonsurgical and surgical treatment","volume":"147","author":"Raz","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.annonc.2021.01.003_bib55","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1002\/cam4.1515","article-title":"Assessment of the prognostic factors in patients with pulmonary carcinoid tumor: a population-based study","volume":"7","author":"Huang","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.annonc.2021.01.003_bib56","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.athoracsur.2017.07.049","article-title":"Extent of resection and lymph node assessment for clinical stage T1aN0M0 typical carcinoid tumors","volume":"105","author":"Brown","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib57","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ejcts\/ezy250","article-title":"Anatomical resections are superior to wedge resections for overall survival in patients with Stage 1 typical carcinoids","volume":"55","author":"Filosso","year":"2019","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib58","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2019.11.006","article-title":"The role of surgery for atypical bronchopulmonary carcinoid tumor: development and validation of a model based on Surveillance, Epidemiology, and End Results (SEER) database","volume":"139","author":"Chen","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2021.01.003_bib59","doi-asserted-by":"crossref","first-page":"423","DOI":"10.21037\/atm.2017.08.13","article-title":"Surgical treatment of synchronous multiple neuroendocrine lung tumours (case series): is more always better?","volume":"5","author":"Brandolini","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.annonc.2021.01.003_bib60","first-page":"1","article-title":"eds., Union for International Cancer Control","author":"Brierley","year":"2017","journal-title":"TNM Classification of Malignant Tumours. 8th ed. Wiley-Blackwell"},{"key":"10.1016\/j.annonc.2021.01.003_bib61","doi-asserted-by":"crossref","first-page":"R261","DOI":"10.1530\/ERC-16-0538","article-title":"Effect of hormone secretory syndromes on neuroendocrine tumor prognosis","volume":"24","author":"Zandee","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.annonc.2021.01.003_bib62","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000484984","article-title":"Endobronchial treatment for bronchial carcinoid: patient selection and predictors of outcome","volume":"95","author":"Reuling","year":"2018","journal-title":"Respiration"},{"key":"10.1016\/j.annonc.2021.01.003_bib63","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000461583","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors","volume":"105","author":"Kaltsas","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.annonc.2021.01.003_bib64","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib65","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.chest.2020.01.031","article-title":"Somatostatin analogs improve respiratory symptoms in patients with diffuse idiopathic neuroendocrine cell hyperplasia","volume":"158","author":"Al-Toubah","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.annonc.2021.01.003_bib66","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1023\/A:1012569909313","article-title":"Experience in treatment of metastatic pulmonary carcinoid tumors","volume":"12","author":"Granberg","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib67","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib68","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1530\/EJE-14-0630","article-title":"GEP-NETS update. Interventional radiology: role in the treatment of liver metastases from GEP-NETs","volume":"172","author":"de Baere","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.annonc.2021.01.003_bib69","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","article-title":"90Y-edotreotide for metastatic carcinoid refractory to octreotide","volume":"28","author":"Bushnell","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib70","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.annonc.2021.01.003_bib71","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.01.003_bib72","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/EJE-19-0877","article-title":"Management of endocrine disease: Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion","volume":"182","author":"Young","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.annonc.2021.01.003_bib73","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1245\/s10434-017-5839-x","article-title":"Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database","volume":"24","author":"Fairweather","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib74","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00330-014-3202-1","article-title":"Thermal ablation techniques: a curative treatment of bone metastases in selected patients?","volume":"24","author":"Deschamps","year":"2014","journal-title":"Eur Radiol"},{"key":"10.1016\/j.annonc.2021.01.003_bib75","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.hpb.2018.12.014","article-title":"Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis","volume":"21","author":"Frilling","year":"2019","journal-title":"HPB"},{"key":"10.1016\/j.annonc.2021.01.003_bib76","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejca.2016.11.034","article-title":"Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids","volume":"75","author":"Sullivan","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.01.003_bib77","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cllc.2016.11.004","article-title":"Outcome analysis of first-line somatostatin analog treatment in metastatic pulmonary neuroendocrine tumors and prognostic significance of 18FDG-PET\/CT","volume":"18","author":"Bongiovanni","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.annonc.2021.01.003_bib78","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.01.003_bib79","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/cas.13427","article-title":"Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis","volume":"109","author":"Fazio","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.annonc.2021.01.003_bib80","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S1470-2045(17)30471-0","volume":"18","author":"Pavel","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib81","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1378\/chest.12-1108","article-title":"Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study","volume":"143","author":"Fazio","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.annonc.2021.01.003_bib82","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.ejca.2013.06.042","article-title":"Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group(GETNE0801)","volume":"49","author":"Castellano","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2021.01.003_bib83","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1471-2407-14-184","article-title":"Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study","volume":"14","author":"Berruti","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annonc.2021.01.003_bib84","doi-asserted-by":"crossref","first-page":"v851","DOI":"10.1093\/annonc\/mdz394.073","article-title":"Efficacy and safety of surufatinib in patients with well differentiated advanced extra-pancreatic neuoendocrine tumors (NETs): results from the randomized phase III study (SANET-ep)","volume":"30","author":"Xu","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib85","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1136\/jclinpath-2012-201329","article-title":"Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma","volume":"66","author":"Nakamura","year":"2013","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.annonc.2021.01.003_bib86","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1159\/000444087","article-title":"Oxaliplatin-based chemotherapy in advanced neuroendocrine tumors: clinical outcomes and preliminary correlation with biological factors","volume":"103","author":"Spada","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.annonc.2021.01.003_bib87","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.1984.2.11.1255","article-title":"Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor","volume":"2","author":"Engstrom","year":"1984","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib88","first-page":"327","article-title":"Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome","volume":"2","author":"Moertel","year":"1979","journal-title":"Cancer Clin Trials"},{"key":"10.1016\/j.annonc.2021.01.003_bib89","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1200\/JCO.2005.03.616","article-title":"Phase II\/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281","volume":"23","author":"Sun","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.annonc.2021.01.003_bib90","doi-asserted-by":"crossref","first-page":"S773","DOI":"10.1016\/j.annonc.2020.08.1374","article-title":"1161MO Lanreotide autogel (LAN) and temozolomide (TMZ) combination therapy in progressive thoracic neuroendocrine tumours (TNETs): ATLANT study results","volume":"31","author":"Ferolla","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib91","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000345938","article-title":"Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series","volume":"97","author":"Saranga-Perry","year":"2013","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.annonc.2021.01.003_bib92","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1634\/theoncologist.2019-0361","article-title":"Capecitabine and temozolomide in advanced lung neuroendocrine neoplasms","volume":"25","author":"Al-Toubah","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2021.01.003_bib93","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"NETTER-1 trial investigators: phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.01.003_bib94","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00259-015-3262-8","article-title":"Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET","volume":"43","author":"Ianniello","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.annonc.2021.01.003_bib95","first-page":"74","article-title":"Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis","volume":"7","author":"Sabet","year":"2017","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.annonc.2021.01.003_bib96","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib97","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2021.01.003_bib98","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.2016.70.4072","article-title":"Phase III prospective randomized comparison trial of depot octreotide plus interferon alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518","volume":"35","author":"Yao","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib99","doi-asserted-by":"crossref","first-page":"e000530","DOI":"10.1136\/jitc-2020-000530","article-title":"A\u00a0first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors","volume":"8","author":"Naing","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2021.01.003_bib100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lungcan.2020.08.001","article-title":"Lung carcinoids with high proliferative activity: further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms","volume":"148","author":"Rubino","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2021.01.003_bib101","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.athoracsur.2013.05.047","article-title":"Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance","volume":"96","author":"Lou","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib102","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.athoracsur.2014.04.020","article-title":"Postsurgical follow-up is always necessary in bronchial carcinoid","volume":"98","author":"Ferolla","year":"2014","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib103","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejcts.2006.10.040","article-title":"Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients","volume":"31","author":"Rea","year":"2007","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.annonc.2021.01.003_bib104","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.01.003_bib105","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"}],"updated-by":[{"DOI":"10.1016\/j.annonc.2021.08.2150","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000}}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421000119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421000119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T09:18:59Z","timestamp":1698916739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421000119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0923753421000119"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.01.003","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.annonc.2021.08.2150","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}